Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Bladder Cancer, September 2025 Free Subscription Abstracts Retrieve all available abstracts of the following 230 articles: HTML format

Single Articles

1. KIM JM, Park S
   Risk stratification of pT1b urothelial carcinoma based on spatial relationships between invasive tumour and muscularis propria on TURB specimens for predicting muscle-invasive urothelial carcinoma in radical cystectomy: A new proposal.
   Malays J Pathol. 2025;47:247-252.
   PubMed    
   Abstract available
   
   

2. QUYNH NT, Nagata Y, Matsukawa T, Kashiwagi E, et al
   Pioglitazone Suppresses Urothelial Tumorigenesis In Vitro: A Potential Chemopreventive Agent.
   Cancer Genomics Proteomics. 2025;22:750-759.
   PubMed    
   Abstract available
   
   

3. NAHKURI S, Weidle UH
   Bladder Cancer: Role of Circular RNAs in Oncogenesis, Tumor Suppression, and Therapeutic Target Identification.
   Cancer Genomics Proteomics. 2025;22:654-682.
   PubMed    
   Abstract available
   
   

4. LIU J, Liu YX, Song YS, Liu CK, et al
   Targeting GRB2-Akt-SREBP1 signaling axis by saponins from Paris polyphylla Smith var. yunnanensis (Franch.) Hand.-Mazz to overcome cisplatin resistance in bladder cancer.
   J Ethnopharmacol. 2025 Aug 27:120502. doi: 10.1016/j.jep.2025.120502.
   PubMed    
   Abstract available
   
   

5. CHEN B, Zhang T, Wang Y, Li Z, et al
   Elevated C-reactive protein and D-dimer to predict venous thromboembolism in patients with bladder cancer.
   Front Immunol. 2025;16:1652139.
   PubMed    
   Abstract available
   
   

6. HAN YE, Sung DJ, Cho HY, Yang KS, et al
   Multiparametric MRI Features of Plasmacytoid Urothelial Carcinoma of the Urinary Bladder.
   Korean J Radiol. 2025;26:832-840.
   PubMed    
   Abstract available
   
   

7. LI Y, Liu S, Zhou M, Zhao Z, et al
   A COX-2-Targeted Platinum(lV) Prodrug Induces Apoptosis and Reduces Inflammation in Bladder Cancer Models.
   Pharmaceuticals (Basel). 2025;18:1185.
   PubMed    
   Abstract available
   
   

8. GHERASIM RD, Chibelean C, Porav-Hodade D, Todea-Moga C, et al
   Microbiome Shifts in Bladder Cancer: A Narrative Review of Urobiome Composition, Progression, and Therapeutic Impact.
   Medicina (Kaunas). 2025;61:1401.
   PubMed    
   Abstract available
   
   

9. DULF DV, Burnar AL, Dulf PL, Matei DR, et al
   Risk Stratification Using a Perioperative Nomogram for Predicting the Mortality of Bladder Cancer Patients Undergoing Radical Cystectomy.
   J Clin Med. 2025;14:5810.
   PubMed    
   Abstract available
   
   

10. GARCIA-RAYO C, Juste-Alvarez S, Gomez-Canizo C, Hernandez-Arroyo M, et al
    The Dynamic Field of Perioperative Treatment for Localized Muscle-Invasive Bladder Cancer: A Review of the Current Research Landscape.
    J Clin Med. 2025;14:5653.
    PubMed    
    Abstract available
    
    

11. VERA G, Cerda-Infante J, Fernandez MI, Sanchez-Encinas M, et al
    Advances in Label-Free Detection of Non-Muscle Invasive Bladder Cancer: A Critical Review.
    Bioengineering (Basel). 2025;12:866.
    PubMed    
    Abstract available
    
    

12. ARTILES MEDINA A, Bajawi Carretero M, Lopez Perez E, Garach Fernandez S, et al
    Impact of Preoperative CT-Diagnosed Sarcopenic Obesity on Outcomes After Radical Cystectomy for Bladder Cancer.
    Cancers (Basel). 2025;17:2669.
    PubMed    
    Abstract available
    
    

13. SHABBIR R, Quiles CG, Lane B, Zeef L, et al
    Gene Expression in Muscle-Invasive and Non-Muscle-Invasive Bladder Cancer Cells Exposed to Hypoxia.
    Cancers (Basel). 2025;17:2624.
    PubMed    
    Abstract available
    
    

14. JANG SH, Kim MS
    Canonical correlations among symptom clusters, symptom experience, and symptom cluster management in male patients with non-muscle invasive bladder cancer: a cross-sectional study.
    Eur J Oncol Nurs. 2025;78:102941.
    PubMed    
    Abstract available
    
    

15. IKUMA S, Akatsuka J, Kaneko G, Takeda H, et al
    Prognostic Utility of Combining VI-RADS Scores and CYFRA 21-1 Levels in Bladder Cancer: A Retrospective Single-Center Study.
    Curr Oncol. 2025;32:415.
    PubMed    
    Abstract available
    
    

16. KAMATANI T, Umeda K, Iwasawa T, Miya F, et al
    Clonal diversity shapes the tumour microenvironment leading to distinct immunotherapy responses in metastatic urothelial carcinoma.
    Nat Commun. 2025;16:7995.
    PubMed    
    Abstract available
    
    

17. MAHMOUDNEJAD N, Hamidi Madani M, Montazeri P, Vakili K, et al
    Clinical Predictive Factors for Reproductive Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Radical Cystectomy Cases from Two Tertiary Centers.
    Iran J Med Sci. 2025;50:530-538.
    PubMed    
    Abstract available
    
    

18. TSENG WH, Lee CH, Lin RJ, Ho CH, et al
    Risk of Bladder Cancer in Patients with Chronic Indwelling Catheters: A Real-World Data Analysis.
    J Cancer. 2025;16:3464-3472.
    PubMed    
    Abstract available
    
    

19. AKINTELURE D, Akintelure S, Al-Ibraheem HA
    Emerging Role of Multiparametric MRI in the Staging of Bladder Cancer: Insights From the BladderPath Trial.
    Cureus. 2025;17:e88623.
    PubMed    
    Abstract available
    
    

20. JOHANSSON HB, Liedberg F, Bernardo C, Zadoroznyj A, et al
    Evaluation of gene expression-based predictors of lymph node metastasis in bladder cancer.
    Bladder Cancer. 2025;11:23523735251370895.
    PubMed    
    Abstract available
    
    

21. CORDARO F, Barresi A, Bencivinni F, Banco A, et al
    Carcinomatous leptomeningitis from bladder cancer mimicking immune-related cerebellitis: A case report.
    Neurol Sci. 2025 Aug 27. doi: 10.1007/s10072-025-08425.
    PubMed    
    Abstract available
    
    

22. WANG D, Ai L, Tan H, Yan Y, et al
    A urinary DNA methylation assay using two genes enables noninvasive detection and prognostic prediction in urothelial carcinoma.
    Sci Rep. 2025;15:31281.
    PubMed    
    Abstract available
    
    

23. HAN G, Wang X, Li Z, Yang K, et al
    Robot-Assisted Boari-flap after Orthotopic Neobladder Using the KangDuo Surgical Robot-01 System.
    Int Braz J Urol. 2026;52:e20250341.
    PubMed    
    Abstract available
    
    

24. VOLZ Y, Eismann L, Westhofen T, Pyrgidis N, et al
    Physical activity matters: prognostic impact of preoperative functioning scores in patients undergoing radical cystectomy.
    World J Urol. 2025;43:512.
    PubMed    
    Abstract available
    
    

25. LIU Z, Cong X, Chen C, Yin J, et al
    Development and landscape of maintenance therapy after first-line treatment of advanced or metastatic urothelial carcinoma.
    Front Immunol. 2025;16:1541213.
    PubMed    
    Abstract available
    
    

26. ATSUTA M, Urabe F, Iwatani K, Kubo M, et al
    Clinical utility of a novel perioperative quality assessment metric, trifecta, for radical cystectomy.
    Int J Clin Oncol. 2025;30:1832-1840.
    PubMed    
    Abstract available
    
    

27. JURADO LF, Daman AW, Li Z, Ross VMS, et al
    A fungal-derived adjuvant amplifies the antitumoral potency of Bacillus Calmette-Guerin via reprogramming granulopoiesis.
    Immunity. 2025;58:1984-2001.
    PubMed    
    Abstract available
    
    

28. RIZKALLA CN, Tretiakova M, Suarez CJ, Williamson SR, et al
    Urothelial carcinoma with osteoclast-like giant cells: An expanded immunohistochemical and molecular profile.
    Am J Clin Pathol. 2025;164:257-264.
    PubMed    
    Abstract available
    
    

29. SU X, Mo X, Kan J, Yang F, et al
    Decoding the genetic links between substance use disorder and cancer vulnerability.
    Psychopharmacology (Berl). 2025;242:2021-2033.
    PubMed    
    Abstract available
    
    

30. CHANG KH, Chen HC, Chen CY, Tsai SP, et al
    Natural lignan justicidin A-induced mitophagy as a targetable niche in bladder cancer.
    Chem Biol Interact. 2025 Sep 3:111723. doi: 10.1016/j.cbi.2025.111723.
    PubMed    
    Abstract available
    
    

31. MISRA S, Bisht R, Motiwala ZY, Puniyani A, et al
    Is it prime time for stent-less robotic radical cystectomy? A scoping review.
    J Robot Surg. 2025;19:560.
    PubMed    
    Abstract available
    
    

32. WANG B, Wu K, Cui Y, Han X, et al
    Effects of a Dendritic Cell Vaccine Loaded With Whole Tumor Antigen on Bladder Cancer Model in hu-PBL-SCID Mice.
    Drug Dev Res. 2025;86:e70157.
    PubMed    
    Abstract available
    
    

33. CHAUMEL M, Brichart N, Bruyere F, Bourgi A, et al
    Impact of COVID-19 care reorganization on the prognosis of patients with bladder urothelial carcinoma: a multicentric retrospective study.
    Can J Urol. 2025;32:359-366.
    PubMed    
    Abstract available
    
    

34. TAN Z, Huang Y, Fu S, Li H, et al
    Construction of a gene-metabolite-microbiome regulatory network reveals novel therapeutic targets in bladder cancer through multi-omics analysis.
    Ann Med. 2025;57:2553220.
    PubMed    
    Abstract available
    
    

35. DEYHIMFAR R, Gholami K, Oskouie IM, Baghdadabad LZ, et al
    High-dose vitamin C improves BCG immunotherapy's efficacy in a murine ectopic model of bladder cancer.
    Pathol Res Pract. 2025;275:156207.
    PubMed    
    Abstract available
    
    

36. GENG R, Shang H, Chen Z, Tang K, et al
    ROS-responsive resiquimod prodrug nanoparticles for macrophage reprogramming and enhanced immune checkpoint inhibitor therapy in bladder cancer.
    Biomaterials. 2025;326:123677.
    PubMed    
    Abstract available
    
    

37. CARAPITO A, Fernandes Ferreira VS, Silva Ferreira AC, Teixeira-Marques A, et al
    Non-invasive bladder cancer detection: Identification of a urinary volatile biomarker panel using GC-MS metabolomics and machine learning.
    Talanta. 2025;297.
    PubMed    
    Abstract available
    
    

38. CHIUJDEA S, Petrut B, Martha O, Chiujdea AL, et al
    Prognostic Factors of Long-Term Survival in Non-Muscle-Invasive Bladder Cancer: An 18-Year Retrospective Study from Real-Life Practice.
    Chirurgia (Bucur). 2025;120:459-466.
    PubMed    
    Abstract available
    
    

39. RADU CG, Radavoi GD, Aurelian J, Achim IF, et al
    Bricker Urinary Diversion after Radical Cystectomy: A Comparative Analysis of Laparoscopic vs. Robotic Approach in Terms of Quality of Life, Perioperative Outcomes and Postoperative Complications.
    Chirurgia (Bucur). 2025;120:446-458.
    PubMed    
    Abstract available
    
    

40. JEONG IS, Seo JW, Park SJ, Kim SY, et al
    Deep learning-driven whole-slide image analysis predicts chemo-resistance and motility subtypes in muscle-invasive bladder cancer.
    Genes Genomics. 2025 Sep 4. doi: 10.1007/s13258-025-01677.
    PubMed    
    Abstract available
    
    

41. BIGLIA A, Sacchi MC, Maggiore F, Morandi V, et al
    Case report: atypical anti-SAE1 autoantibody manifestation with splinter hemorrhages as onset, and related to urothelial cancer.
    Eur Rev Med Pharmacol Sci. 2025;29:398-403.
    PubMed    
    Abstract available
    
    

42. MENG L, Zhu X, Ji X, Wang B, et al
    Advances in the immunological microenvironment and immunotherapy of bladder cancer.
    Front Immunol. 2025;16:1609871.
    PubMed    
    Abstract available
    
    

43. BAKALOUDI DR, Koehne EL, Voutsinas JM, Diamantopoulos LNu, et al
    Agreement between transurethral resection of bladder tumor and radical cystectomy pathology in patients with bladder cancer subtype histology: A retrospective cohort study.
    Urol Oncol. 2025 Sep 2:S1078-1439(25)00282-0. doi: 10.1016/j.urolonc.2025.
    PubMed    
    Abstract available
    
    

44. MAURYA N, Singh R, Goel A, Singhai A, et al
    Correction to "Clinicohistopathological implications of phosphoserine 9 glycogen synthase kinase-3beta/ beta-catenin in urinary bladder cancer patients".
    World J Clin Oncol. 2025;16:107778.
    PubMed    
    Abstract available
    
    

45. SO SW, Han JH, Yuk HD, Jeong CW, et al
    High carbohydrate antigen 19-9 levels indicate poor prognosis in patients with bladder cancer following radical cystectomy.
    Front Oncol. 2025;15:1550203.
    PubMed    
    Abstract available
    
    

46. RINGIA JB, Scholte FEF, Lijnen RAG, Algie E, et al
    Routine annual imaging does not aid in diagnosing new functional complications more than five years after RC with ileal conduit.
    World J Urol. 2025;43:539.
    PubMed    
    Abstract available
    
    

47. MALMSTROM PU, Wang EYH
    Paradigm shift in the treatment of bladder cancer? The Swedish perspective.
    Scand J Urol. 2025;60:186-188.
    PubMed    
    Abstract available
    
    

48. LIEDBERG F, Baseckas G, Blackberg M, Fridriksdottir R, et al
    Survival patterns after perioperative treatment escalation and cystectomy for synchronous oligometastatic bladder cancer (M1a/M1b) - a population-based series.
    Scand J Urol. 2025;60:173-179.
    PubMed    
    Abstract available
    
    

49. CHUANG AE, Tao YK, Fan YJ, Chiu HJ, et al
    Synergistic nanoplatform of M1 macrophage-derived extracellular vesicles and MoS(2) for tumor-targeted photoimmunotherapy in bladder cancer.
    Nanoscale. 2025 Sep 3. doi: 10.1039/d5nr00374.
    PubMed    
    Abstract available
    
    

50. LI T, Zhu K, Tong H, Sun Y, et al
    Cancer-associated fibroblast derived CXCL14 drives cisplatin chemoresistance by enhancing nucleotide excision repair in bladder cancer.
    J Exp Clin Cancer Res. 2025;44:265.
    PubMed    
    Abstract available
    
    

51. PARK JH, Lee S, Jeong SH, Ku JH, et al
    The effect of neoadjuvant chemotherapy on survival outcomes subsequent to radical cystectomy in pathological T0 bladder cancer patients: A multicenter large-scale analysis.
    Investig Clin Urol. 2025;66:395-404.
    PubMed    
    Abstract available
    
    

52. OH JJ, Hong SK
    Contemporary management of metastatic urothelial carcinoma.
    Investig Clin Urol. 2025;66:375-382.
    PubMed    
    Abstract available
    
    

53. SAHARTI SN, Almutairi FM
    Trends in genitourinary tumors: Academic center experience over 16 years.
    Saudi Med J. 2025;46:985-991.
    PubMed    
    Abstract available
    
    

54. MOSE L, Maitre P, Eberz P, Zilli T, et al
    Treatment approaches for non-metastatic small cell bladder cancer: a meta-analysis of reconstructed Kaplan-Meier curves.
    Clin Transl Radiat Oncol. 2025;55:101032.
    PubMed    
    Abstract available
    
    

55. SHI M, Meng X, Xu X, Wang Q, et al
    Gene and pathway analysis of genome-wide genetic associations of bladder cancer.
    Curr Urol. 2025;19:321-330.
    PubMed    
    Abstract available
    
    

56. GONZALEZ V, Linton E, Boyce T, Dahmoush L, et al
    Novel use of carboplatin, etoposide and durvalumab as neoadjuvant therapy in treatment of small cell bladder cancer.
    Urol Case Rep. 2025;62:103165.
    PubMed    
    Abstract available
    
    

57. WANG T, Ding F, Sun K
    Construction and immunohistochemical validation of a necroptosis-related prognostic signature in bladder cancer and its association with tumor immune infiltration.
    Front Genet. 2025;16:1527907.
    PubMed    
    Abstract available
    
    

58. XU D, Li Q
    Molecular Characteristics, Heterogeneity, Plasticity, and Cell of Origin of Neuroendocrine Bladder Cancer.
    Cancer Heterog Plast. 2025;2:10.
    PubMed    
    Abstract available
    
    

59. DING Y, Pan Y, Geyer CR, Vizeacoumar FJ, et al
    Unraveling bladder cancer-related circRNA biomarkers: a hybrid model combining deep learning and statistics.
    Health Inf Sci Syst. 2025;13:53.
    PubMed    
    Abstract available
    
    

60. ALIMOHAMED NS, Gotto G, Kulkarni GS, Black PC, et al
    A population-based analysis of patterns of care in patients with de novo muscle-invasive bladder cancer from Alberta, Canada.
    Can Urol Assoc J. 2025 Aug 28. doi: 10.5489/cuaj.9111.
    PubMed    
    Abstract available
    
    

61. KANAAN MF, Breau RH, Lavallee LT, McIsaac DI, et al
    Testosterone replacement therapy and bladder cancer.
    Can Urol Assoc J. 2025 Aug 28. doi: 10.5489/cuaj.9207.
    PubMed    
    Abstract available
    
    

62. POOCHI SP, Sundarraj R, Raju MV, Kaniyur Chandrasekaran M, et al
    Harnessing Nature: Computational and Experimental Insights Into Ipomoea obscura Metabolites for Bladder Cancer Therapy.
    Chem Biodivers. 2025 Sep 2:e00909. doi: 10.1002/cbdv.202500909.
    PubMed    
    Abstract available
    
    

63. AN W, Shen D, Li D, Shen J, et al
    Unmasking disparities in bladder cancer outcomes in the disaggregated Asian American population.
    Expert Rev Anticancer Ther. 2025 Sep 3:1-10. doi: 10.1080/14737140.2025.2556884.
    PubMed    
    Abstract available
    
    

64. SHI Z, Luo Z, Luo W, Zhao B, et al
    Letter to the editor: "bladder cancer isn't BPH: why TURBT patients deserve separate risk models for complicated UTI".
    World J Urol. 2025;43:527.
    PubMed    
    
    
    

65. SORIA F, Mari A, Moschini M, Naspro R, et al
    The current role of photodynamic diagnosis (PDD) in the management of non-muscle invasive bladder cancer: the Italian Society of Urology (SIU) Position Paper.
    Minerva Urol Nephrol. 2025;77:443-450.
    PubMed    
    Abstract available
    
    

66. ERNST VS, Manz K, Weitmann K, Hoffmann W, et al
    Assessing cancer risk in firefighters in Northern Germany: a retrospective cohort study.
    BMC Public Health. 2025;25:2998.
    PubMed    
    Abstract available
    
    

67. CHEN K, Chen J, Cong Y, He Q, et al
    Correction: TTK promotes mitophagy by regulating ULK1 phosphorylation and pre-mRNA splicing to inhibit mitochondrial apoptosis in bladder cancer.
    Cell Death Differ. 2025 Sep 1. doi: 10.1038/s41418-025-01571.
    PubMed    
    
    
    

68. ZHAO L, Xu Z, Ren L, Zheng S, et al
    Investigating the relationship between peripheral blood transferrin receptor protein and tumor cell ferroptosis, invasion, and metastasis in bladder cancer.
    Sci Rep. 2025;15:32197.
    PubMed    
    Abstract available
    
    

69. DU C, Wei W, Hu M, He J, et al
    Multi-DECT Image-based Interpretable Model Incorporating Habitat Radiomics and Vision Transformer Deep Learning for Preoperative Prediction of Muscle Invasion in Bladder Cancer.
    Acad Radiol. 2025 Aug 30:S1076-6332(25)00756-1. doi: 10.1016/j.acra.2025.
    PubMed    
    Abstract available
    
    

70. HU L, Hu JW, Wang CQ, Li RY, et al
    Neoadjuvant PD-1/PD-L1 Inhibitors for Muscle-Invasive Bladder Cancer: A Meta-Analysis.
    Clin Genitourin Cancer. 2025;23:102408.
    PubMed    
    Abstract available
    
    

71. LINDLAND K, Juzeniene A
    Cytotoxicity of (212)Pb-labeled anti-PTK7 antibody in 2D adherent and 3D multicellular bladder cancer models.
    EJNMMI Radiopharm Chem. 2025;10:58.
    PubMed    
    Abstract available
    
    

72. NECCHI A, Guerrero-Ramos F, Crispen PL, Herrera-Imbroda B, et al
    TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a randomised, open
    Lancet Oncol. 2025 Aug 27:S1470-2045(25)00358.
    PubMed    
    Abstract available
    
    

73. MI W, Zang C, Zhao J, Kamat AM, et al
    Mixed-grade papillary urothelial carcinoma with a minor high-grade component shows a significantly worse clinical outcome than low-grade papillary urothelial carcinoma.
    Hum Pathol. 2025;163:105904.
    PubMed    
    Abstract available
    
    

74. CHAN E, Stohr BA, Sangoi AR, Sirohi D, et al
    Invasive urothelial carcinoma with chordoid and myxoid features shows increased RAS/RAF pathway alterations.
    Hum Pathol. 2025;163:105882.
    PubMed    
    Abstract available
    
    

75. POWLES TB, Grande E, Alimohamed N, Oliveira N, et al
    SGNDV-001: disitamab vedotin with pembrolizumab in HER2-expressing locally advanced or metastatic urothelial carcinoma.
    Future Oncol. 2025;21:2705-2712.
    PubMed    
    Abstract available
    
    

76. WANG XL, Cao L, Wang YW, Chu T, et al
    Role of 3-mercaptopyruvate sulfurtransferase in cancer.
    Cell Signal. 2025;135:112020.
    PubMed    
    Abstract available
    
    

77. AMINSHARIFI A, Saran Manivasagam S, Askarpour MR, Raman JD, et al
    Is organ preserving radical cystectomy in women oncologically safe and does it improve quality of life?
    Expert Rev Anticancer Ther. 2025;25:1075-1085.
    PubMed    
    Abstract available
    
    

78. INDULKAR S, Rao BV, Das D, Pasam MK, et al
    Deciphering the Molecular Landscape of Urothelial Carcinoma: Immunohistochemistry-based Subtyping Using 4 Easily Available Antibodies for Cost-effective Stratification.
    Appl Immunohistochem Mol Morphol. 2025;33:267-276.
    PubMed    
    Abstract available
    
    

79. DELAHUNT B, Johannsen S, Egevad L, Yaxley JW, et al
    High proportion of clinically significant prostate adenocarcinomas in radical cystoprostatectomy specimens following complete prostate sampling.
    Pathology. 2025;57:708-711.
    PubMed    
    Abstract available
    
    

80. SABER TANHA A, Raeisi N, Jafari Zarrin Ghabaei F, Aryana K, et al
    Comparable Diagnostic Performance of 99m Tc-FAPI Scintigraphy and Contrast-enhanced CT in Restaging a Rare Case of Metastatic Colon Adenocarcinoma to the Urachus.
    Clin Nucl Med. 2025;50:e626-e627.
    PubMed    
    Abstract available
    
    

81. UNTERRAINER LM, Schmid HP, Kunte SC, Holzgreve A, et al
    (68)Ga-FAPI and (18)F-FAPI PET/CT for detection of nodal metastases prior radical cystectomy in high-risk urothelial carcinoma patients.
    Eur J Nucl Med Mol Imaging. 2025;52:3963-3974.
    PubMed    
    Abstract available
    
    

82. PERLIN D V, Shmanev A O, Shamkhalov Sh N, Zipunnikov V P, et al
    [Recurrence of urothelial bladder cancer in the upper urinary tract after radical cystectomy: is there prevention and what are the treatment options?].
    Urologiia. 2025;:59-63.
    PubMed    
    Abstract available
    
    

83. DMITRIEVA T A, Popov A Y, Gritskevich A A, Makarov V A, et al
    [Review of current methods of diagnosis and treatment of locally advanced urothelial bladder cancer].
    Urologiia. 2025;:96-102.
    PubMed    
    Abstract available
    
    

84. AKINTELURE D, Tawose P, Akintelure S, Agada R, et al
    Tropomyosin Isoforms as Biomarkers for Urothelial Bladder Cancer: Promise and Challenges.
    Cureus. 2025;17:e89801.
    PubMed    
    Abstract available
    
    

85. CHE K, Qian D, Cui S, Xie F, et al
    Dissecting Causal Relationships Between Gut Microbiota, Plasma Metabolites and Bladder Cancer: A Two-Step Mendelian Randomization Study.
    Health Sci Rep. 2025;8:e71206.
    PubMed    
    Abstract available
    
    

86. HUANG J, Zhou C, Yu Z, Song Z, et al
    A novel prognostic biomarker DUSP6 promote the malignant progression of bladder cancer through mTOR mediated mitophagy.
    Front Oncol. 2025;15:1603069.
    PubMed    
    Abstract available
    
    

87. ZHOU Q, Ma L, Yu Y, Zhang C, et al
    Development of a radiomics and clinical feature-based nomogram for preoperative prediction of pathological grade in bladder cancer.
    Front Oncol. 2025;15:1661979.
    PubMed    
    Abstract available
    
    

88. PETRELLI F, Dottorini L, Ghidini A, Ceresoli F, et al
    Comparison of adjuvant and neoadjuvant therapies for muscle invasive bladder cancer: A network meta-analysis.
    Urol Oncol. 2025 Sep 10:S1078-1439(25)00333.
    PubMed    
    Abstract available
    
    

89. LIU Y, Liu L, Yao Z, Hou Y, et al
    Applications and future prospects of laser technologies in the treatment of non-muscle invasive bladder cancer.
    Bladder (San Franc). 2025;12:e21200050.
    PubMed    
    Abstract available
    
    

90. ZHONG H, He W, Mo M, Tong S, et al
    Neoadjuvant therapy plus thulium laser transurethral bladder tumor resection for muscle-invasive bladder cancer.
    Bladder (San Franc). 2025;12:e21200053.
    PubMed    
    Abstract available
    
    

91. BENZEKRY I, Klein I, Pavlov A, Dekel Y, et al
    [MASSIVE TUMOR INSIDE A GIANT BLADDER DIVERTICULUM].
    Harefuah. 2025;164:529-531.
    PubMed    
    Abstract available
    
    

92. FAZAA N, Shashar R, Malshy K, Amiel G, et al
    [INNOVATIONS IN THERAPIES FOR BACILLUS CALMETTE-GUERIN (BCG) FAILURE NON-MUSCLE INVASIVE PATIENTS].
    Harefuah. 2025;164:524-528.
    PubMed    
    Abstract available
    
    

93. WEN L, Miyagi H, Spiess PE, Yu A, et al
    Low-grade non-muscle-invasive bladder cancer: molecular landscape, treatment strategies and emerging therapies.
    Nat Rev Urol. 2025 Sep 10. doi: 10.1038/s41585-025-01072.
    PubMed    
    Abstract available
    
    

94. CHANG K, Delavan HM, Yip E, Kasap C, et al
    Modulating the PPARgamma pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer.
    Nat Commun. 2025;16:8215.
    PubMed    
    Abstract available
    
    

95. HOSSAIN MN, Das D, Mostofa MA, Hosen MI, et al
    Targeted hotspot profiling reveals a functionally relevant mutation in bladder cancer.
    Urol Oncol. 2025 Sep 9:S1078-1439(25)00317-5. doi: 10.1016/j.urolonc.2025.
    PubMed    
    Abstract available
    
    

96. YANG X, Wang L, Lin P, Ning Y, et al
    Corrigendum to "Discovery of Artesunate (ARS) PROTACs as GPX4 protein degraders for the treatment of bladder cancer" [Eur. J. Med. Chem. 293 (2025) 117710].
    Eur J Med Chem. 2025 Sep 10:118140. doi: 10.1016/j.ejmech.2025.118140.
    PubMed    
    
    
    

97. SAKATANI T, Tanaka S, Murakami K, Aguilar F, et al
    Development and analytical validation of a multiplex diagnostic qPCR-array as a potential application in predicting the response to neoadjuvant chemotherapy in muscle invasive bladder cancer.
    Transl Oncol. 2025;61:102528.
    PubMed    
    Abstract available
    
    

98. XIE H, Yi X, Wei W
    A commentary on "A nomogram for predicting lymph node metastases in nonmetastatic muscle-invasive bladder cancer: a SEER-based investigation".
    Int J Surg. 2025 Sep 10. doi: 10.1097/JS9.0000000000003346.
    PubMed    
    
    
    

99. MASTROIANNI R, Iannuzzi A, Ragusa A, Tuderti G, et al
    Impact of pad wetness on health-related quality of life after radical cystectomy and orthotopic neobladder.
    World J Urol. 2025;43:548.
    PubMed    
    Abstract available
    
    

100. LIU L, Liu Z, Fan L, Yao Z, et al
     An evaluation of the tumor microenvironment through CALR, IL1R1, IFNB1, and IFNG to assess prognosis and immunotherapy response in bladder cancer patients.
     Elife. 2025;13:RP95326.
     PubMed    
     Abstract available
     
     

101. ZHANG D, Ren J, Ye J, Wu R, et al
     Bladder cancer risk factors: a comprehensive umbrella review of meta-analyses.
     Int J Surg. 2025 Sep 10. doi: 10.1097/JS9.0000000000003371.
     PubMed    
     Abstract available
     
     

102. CHAVES MEDINA MJ, Villada Florez D, Castaneda Millan DA, Garcia-Perdomo HA, et al
     Using epigenetics as an alternative treatment for bladder cancer: A literature review.
     Urologia. 2025 Sep 10:3915603251372377. doi: 10.1177/03915603251372377.
     PubMed    
     Abstract available
     
     

103. DONG J, Guo Y, Ji T, Guan H, et al
     Puerariae radix flavones induce apoptosis in bladder cancer T24 cells via the FAS/TNFR1 pathway: A potential therapeutic candidate.
     Biomed Rep. 2025;23:170.
     PubMed    
     Abstract available
     
     

104. LI J, Song Y, Chen R, Gao H, et al
     Evaluating repeat transurethral resection after en bloc resection for non-muscle invasive bladder cancer.
     Ther Adv Urol. 2025;17:17562872251367555.
     PubMed    
     Abstract available
     
     

105. CAO T, Li N, Guo C, Zhang H, et al
     CT-based Radiomics of Intratumoral and Peritumoral Regions to Predict the Recurrence Risk in Patients with Non-muscle-invasive Bladder Cancer within Two Years after TURBT.
     Curr Med Imaging. 2025 May 26. doi: 10.2174/0115734056350444250418075406.
     PubMed    
     Abstract available
     
     

106. BROOKS G, Ghidini F, Virgone C, De Corti F, et al
     Long-term complications in patients with bladder-prostate rhabdomyosarcoma treated with brachytherapy: a systematic review.
     Pediatr Surg Int. 2025;41:290.
     PubMed    
     Abstract available
     
     

107. XIE JL, Li XJ, Zhang YL, Zheng YY, et al
     [Primary lymphomas in urinary bladder: a clinicopathological analysis of 23 cases].
     Zhonghua Bing Li Xue Za Zhi. 2025;54:925-931.
     PubMed    
     Abstract available
     
     

108. LU K, Chao L, Wang J, Wang X, et al
     Erratum: Risk Score Model of Aging-Related Genes for Bladder Cancer and Its Application in Clinical Prognosis.
     JCO Clin Cancer Inform. 2025;9:e2500251.
     PubMed    
     
     
     

109. ZHOU L, Yu G, Zheng Z, Xu B, et al
     IGHA1 and IGHG1 Expression Panel Predicts Anti-PD-L1 Response in Muscle-Invasive Bladder Cancer.
     Mol Carcinog. 2025 Sep 8. doi: 10.1002/mc.70033.
     PubMed    
     Abstract available
     
     

110. DA Y, Lu Z, Zhu Z, Tai H, et al
     A high stroma-tumor ratio is associated with an immunosuppressive tumor microenvironment and a poor prognosis in bladder cancer.
     Front Oncol. 2025;15:1604609.
     PubMed    
     Abstract available
     
     

111. LIU Y, Lv H, Chen Y, Ye S, et al
     Cu(2)(OH)PO(4)@PAA Nanoparticles for Highly Effective Combination of Chemodynamic, Photodynamic and Photothermal Therapies Against Bladder Cancer.
     Int J Nanomedicine. 2025;20:10701-10719.
     PubMed    
     Abstract available
     
     

112. LIU X, Ding G, Liu Y, Yan X, et al
     Epigenetic regulation of bladder cancer in the context of aging.
     Front Pharmacol. 2025;16:1617452.
     PubMed    
     Abstract available
     
     

113. PENG L, Cai T, Xu P, Chen C, et al
     Integrating Spatial Multi-Omics and Machine Learning to Unravel the Role of PANoptosis in Bladder Cancer Prognosis and Immunotherapy Response.
     Oncol Res. 2025;33:2463-2489.
     PubMed    
     Abstract available
     
     

114. HUANG W, Chao F, Hsu JC, Sun X, et al
     Noninvasive ImmunoPET imaging of PD-L1 expression in non-small cell lung cancer and bladder cancer using [(89)Zr]Zr-DFO-Durvalumab.
     Colloids Surf A Physicochem Eng Asp. 2025;723:137332.
     PubMed    
     Abstract available
     
     

115. NAM KC, Park BJ
     Antibacterial and anticancer activity of multifunctional iron-based magnetic nanoparticles against urinary tract infection and cystitis-related bacterial strains and bladder cancer cells.
     Biomed Eng Lett. 2025;15:903-915.
     PubMed    
     Abstract available
     
     

116. WANG L, Ren D, Cai Z, Hu W, et al
     O-GlcNAcylated YTHDF2 promotes bladder cancer progression by regulating the tumor suppressor gene PER1 via m(6)A modification.
     Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2025;50:827-839.
     PubMed    
     Abstract available
     
     

117. MICHALIK T, Wrobel M, Fedorowicz S, Michalik K, et al
     [Bladder cancer in geriatric patients].
     Med Pr. 2025 Sep 1:209113. doi: 10.13075/mp.5893.01621.
     PubMed    
     Abstract available
     
     

118. FANG Q, You C, Xiao X, Liu Y, et al
     Mevalonate Metabolic Reprogramming Drives Cisplatin Resistance in Bladder Cancer: Mechanisms and Therapeutic Targeting.
     Protein Pept Lett. 2025 Sep 3. doi: 10.2174/0109298665403178250806111943.
     PubMed    
     Abstract available
     
     

119. NASSAR O, Farahat IG
     Prostate sparing radical cystectomy and neobladder: institutional long-standing qualified consideration.
     J Egypt Natl Canc Inst. 2025;37:58.
     PubMed    
     Abstract available
     
     

120. BAI K, Pingle SR, Chung R, Joffe BI, et al
     Revisiting BCG: The potential of rescue BCG therapy for BCG-unresponsive non-muscle-invasive bladder cancer.
     Urol Oncol. 2025 Sep 6:S1078-1439(25)00313-8. doi: 10.1016/j.urolonc.2025.
     PubMed    
     Abstract available
     
     

121. CONG B, Liu H, Sun M, Hu D, et al
     Bisphenol A exposure promotes proliferation and invasion capabilities of bladder cancer cells: Insights from gene expression and pathway analysis.
     Toxicol Lett. 2025 Sep 5:S0378-4274(25)01577.
     PubMed    
     Abstract available
     
     

122. WANG K, Gu Q, Xue C, Shi J, et al
     MAP30 inhibits proliferation and metastasis of bladder cancer by increasing EGR1 expression and promoting the transcriptional activation of DUSP1.
     Mol Immunol. 2025;187:48-60.
     PubMed    
     Abstract available
     
     

123. XU X, Liang Z, Feng Y, Qi H, et al
     Preliminary Functional Outcome Following Robotic Intracorporeal Orthotopic Ileal Neobladder with Integrated Pelvic Fascial Structure-Sparing in Males with Bladder Cancer.
     Urol J. 2025 Sep 6. doi: 10.22037/uj.v22i.8450.
     PubMed    
     Abstract available
     
     

124. WANG Z, Shi H, Wang Q, Huang Y, et al
     AI-driven and Traditional Radiomic Model for Predicting Muscle Invasion in Bladder Cancer via Multi-parametric Imaging: A Systematic Review and Meta-analysis.
     Acad Radiol. 2025 Sep 5:S1076-6332(25)00806-2. doi: 10.1016/j.acra.2025.
     PubMed    
     Abstract available
     
     

125. RODRIGUEZ PENARANDA N, Di Bello F, Marmiroli A, Falkenbach F, et al
     Cancer-specific mortality in secondary bladder cancer after nephroureterectomy for upper tract urothelial carcinoma.
     Urol Oncol. 2025 Sep 5:S1078-1439(25)00312-6. doi: 10.1016/j.urolonc.2025.
     PubMed    
     Abstract available
     
     

126. DAI H, Zhang Y, Yu S, Feng Y, et al
     miR-19b-3p Affects the Proliferation and Apoptosis of Bladder Cancer Cells by Regulating the Stability of lncRNA SNHG20.
     Appl Biochem Biotechnol. 2025 Sep 6. doi: 10.1007/s12010-025-05370.
     PubMed    
     Abstract available
     
     

127. ROBERSON DS, McLeay MT 2nd, Henning G, Morales-Martinez G, et al
     The impact of prophylactic incisional negative pressure wound therapy on surgical site infection following open radical cystectomy.
     Urol Oncol. 2025;43:586-593.
     PubMed    
     Abstract available
     
     

128. JUNLAPAK N, Khumngern S, Nontipichet N, Kangkamano T, et al
     A label-free electrochemical immunosensor for bladder tumor marker NMP22 using AuNPs@OMC and Thi@Gr-COOH nanocomposites.
     Bioelectrochemistry. 2026;167:109074.
     PubMed    
     Abstract available
     
     

129. CHOW RD, Mamtani R
     Assessment of synergistic vs. independent drug activity for enfortumab vedotin and pembrolizumab in untreated advanced urothelial carcinoma.
     Urol Oncol. 2025;43:597.
     PubMed    
     Abstract available
     
     

130. HAIDER CG, Wang Q, Wang G, Wang Y, et al
     Copy number variations in urine cell-free DNA from bladder neoplasm patients.
     Mol Cell Probes. 2025;83:102044.
     PubMed    
     Abstract available
     
     

131. MOON HH, Aragon-Ching JB, Thompson A, Abraham A, et al
     Early real-world utilization of avelumab switch maintenance among patients with advanced urothelial carcinoma without progression following treatment with first-line platinum-based chemotherapy.
     Urol Oncol. 2025;43:594.
     PubMed    
     Abstract available
     
     

132. HART LJ, Barker K, Ruzdija D, Bertolo A, et al
     Tumor profiling of advanced urothelial carcinoma: Comparative analysis based on social determinants of health.
     Urol Oncol. 2025;43:596.
     PubMed    
     Abstract available
     
     

133. GAZZONI G, Michelon I, Vilbert M, Oliveira JP, et al
     Enfortumab vedotin-related skin toxicities in patients with urothelial carcinoma: A systematic review and meta-analysis.
     Urol Oncol. 2025;43:595.
     PubMed    
     Abstract available
     
     

134. BERTOLO R, Cianflone F, Pettenuzzo G, Costantino S, et al
     The impact of early versus delayed ureteral ligation on renal function after robot-assisted radical cystectomy.
     Eur J Surg Oncol. 2025;51:110213.
     PubMed    
     Abstract available
     
     

135. HAYASHI A, Maeda S, Yamazaki A, Nakamura T, et al
     Urinary lipid production in dogs with urothelial carcinoma.
     Vet J. 2025;313:106373.
     PubMed    
     Abstract available
     
     

136. CHEN F, Simsir A, Cheng L
     Molecular testing in urinary cytology specimens: Current status and future directions.
     Urol Oncol. 2025;43:565-578.
     PubMed    
     Abstract available
     
     

137. LOPES M, Pereira J, Temido MJ, Gama J, et al
     Prognostic value of combined tumor regression grade and TNM stage in muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy.
     Arch Ital Urol Androl. 2025 Sep 17:14264. doi: 10.4081/aiua.2025.14264.
     PubMed    
     Abstract available
     
     

138. LAI Y, Peng Z, He Z, Lu Z, et al
     Dioscin initiates dual roles in bladder cancer progression via miR-195-5p/FASN/SLC3A2 axis-mediated cell death mechanisms.
     Transl Oncol. 2025;61:102534.
     PubMed    
     Abstract available
     
     

139. SQUIRES P, Cook EE, Song Y, Wang CY, et al
     Real-world economic burden of disease recurrence in patients with muscle-invasive bladder cancer: A population-level claims-based analysis.
     J Manag Care Spec Pharm. 2025 Sep 17:1-11. doi: 10.18553/jmcp.2025.25106.
     PubMed    
     Abstract available
     
     

140. WILLIAMS C, Talwar R, Ramchandani P, Smith AL, et al
     Characterizing pelvic organ descent in women after radical cystectomy: an exploratory analysis.
     World J Urol. 2025;43:559.
     PubMed    
     Abstract available
     
     

141. WANG J, Yang J, Yao K, Tan J, et al
     m6A-modified circCD2AP suppressed ferroptosis in bladder cancer by upregulating FOXC1 to promote PARK7 transcriptional activity.
     Chin Med J (Engl). 2025 Sep 16. doi: 10.1097/CM9.0000000000003744.
     PubMed    
     Abstract available
     
     

142. MARKOVIC G, Resnik N, Janev A, Zupancic D, et al
     The role of focal adhesion kinase in bladder cancer: translation from in vitro to ex vivo human urothelial carcinomas.
     Radiol Oncol. 2025;59:349-367.
     PubMed    
     Abstract available
     
     

143. CHEN H, Ma L, Ji Z, Dong J, et al
     FAM174B remodels the tumor microenvironment, inhibits the infiltration of macrophage, predicts the molecular subtype and therapeutic response of bladder cancer.
     Int J Med Sci. 2025;22:3737-3748.
     PubMed    
     Abstract available
     
     

144. HAN Y, Li C, Wu G
     Comment on "IGF2BP3 promotes the proliferation and cisplatin resistance of bladder cancer by enhancing the mRNA stability of CDK6 in an m(6)A dependent manner".
     Int J Biol Sci. 2025;21:5284-5286.
     PubMed    
     
     
     

145. LANG Y, Li P, He R, Zhu B, et al
     Dynamic changes of urinary microbiota in patients with bladder cancer after surgery and its clinical significance.
     Front Immunol. 2025;16:1638628.
     PubMed    
     Abstract available
     
     

146. HIONG A, Lynam J, Weickhardt A, Wong S, et al
     Perioperative chemotherapy use and related outcomes in muscle-invasive bladder cancer in Australia.
     BJUI Compass. 2025;6:e70083.
     PubMed    
     Abstract available
     
     

147. LIU Y, Li J, Liang G, Fang F, et al
     The mediating effect of dyadic coping between illness perception and fear of disease progression in bladder cancer patients: A cross-sectional survey.
     Medicine (Baltimore). 2025;104:e44520.
     PubMed    
     Abstract available
     
     

148. LIU Z, Tu J, Long J, Guo L, et al
     Causal relationships between immune cells and common urinary system tumors: A bidirectional analysis of Mendelian randomization.
     Medicine (Baltimore). 2025;104:e44297.
     PubMed    
     Abstract available
     
     

149. TIAN S, Wang C, Zhao X, Xuan Y, et al
     A CEBPB/TYMP/GDF15 signaling axis mediates tumor growth and cisplatin resistance in bladder cancer.
     Transl Oncol. 2025;61:102537.
     PubMed    
     Abstract available
     
     

150. GUPTA S, Lee JK, Mitchell J, Huang RSP, et al
     Fibroblast Growth Factor Receptor 3 Alteration Status and Outcomes on Immune Checkpoint Inhibitors in Patients With Metastatic Urothelial Carcinoma.
     JCO Precis Oncol. 2025;9:e2500257.
     PubMed    
     Abstract available
     
     

151. IBRAHEEM N, Abosheisha M, Alemam A, Abbas M, et al
     Integrated Magnetic Resonance Imaging in Muscle-Invasive Bladder Cancer: A Comprehensive Review.
     Cureus. 2025;17:e90077.
     PubMed    
     Abstract available
     
     

152. HABAZ IA, Ou X, Wang NI, Schincaglia A, et al
     MAIT cells promote cancer progression and regulatory T cell accumulation in bladder tumor microenvironment.
     J Immunother Cancer. 2025;13:e012496.
     PubMed    
     Abstract available
     
     

153. SIMOES GCS, Calderon J, Claros OR, Alfer W, et al
     Robotic Partial Cystectomy for Urachal Adenocarcinoma: Surgical Technique with Cys-toscopic Correlation.
     Int Braz J Urol. 2026;52:e20250446.
     PubMed    
     Abstract available
     
     

154. SHEBANI MAA, Ikdees AA, Alazeebi SY, Nagib E, et al
     A Multifactorial Case of Retroperitoneal Fibrosis in a Post-radiation Bladder Cancer Patient: Diagnostic and Therapeutic Challenges.
     Cureus. 2025;17:e89976.
     PubMed    
     Abstract available
     
     

155. SHAO Y, Guan Y, Zhao J, Abudurexiti M, et al
     Alternating intravesical instillation of Bacillus Calmette-Guerin and Pseudomonas aeruginosa effectively prevents postoperative recurrence in high-risk non-muscle-invasive bladder cancer.
     Am J Transl Res. 2025;17:6619-6629.
     PubMed    
     Abstract available
     
     

156. GOTO T, Akai T, Teramoto Y, Miyamoto H, et al
     Latrophilin-1 and latrophilin-2 as androgen receptor-responsive G protein-coupled receptors promote bladder cancer progression.
     Am J Transl Res. 2025;17:6403-6413.
     PubMed    
     Abstract available
     
     

157. HASHIMOTO M, Fukiage K, Taniguchi K, Minami T, et al
     Upper urinary tract urothelial carcinoma patients show better overall response rate than bladder cancer patients during enfortumab vedotin treatment following pembrolizumab.
     Transl Androl Urol. 2025;14:2279-2288.
     PubMed    
     Abstract available
     
     

158. CAO J, Zheng W
     Angiogenesis-related gene NID2 profiling and immune infiltration in bladder cancer: prognostic implications and immunotherapy response.
     Front Immunol. 2025;16:1615173.
     PubMed    
     Abstract available
     
     

159. HUANG X, Wang X, He Z, Huang Y, et al
     Mechanisms, Clinical Trials, and New Treatments for BCG-Unresponsive in Nonmuscle Invasive Bladder Cancer.
     Cancer Med. 2025;14:e71243.
     PubMed    
     Abstract available
     
     

160. DAVIDSSON S, Jerlstrom T, Carlsson J
     Optimizing Tissue Sampling Timing for Accurate Gene Expression Analysis.
     Int J Mol Sci. 2025;26:8581.
     PubMed    
     Abstract available
     
     

161. DEVAR J, Elebo N, Makan A, Pincus A, et al
     Distinct Metabolomic and Lipoprotein Signatures in Gall Bladder Cancer Patients of Black African Ancestry.
     Cancers (Basel). 2025;17:2925.
     PubMed    
     Abstract available
     
     

162. SETTI BOUBAKER N, Gurtner A, Boussetta S, Manni I, et al
     Dysregulated MicroRNAs in Urinary Non-Muscle-Invasive Bladder Cancer: From Molecular Characterization to Clinical Applicability.
     Cancers (Basel). 2025;17:2768.
     PubMed    
     Abstract available
     
     

163. PARK IW, Noh TI, Kang SH, Oh JJ, et al
     Demonstrating the non-inferiority of robotic radical cystectomy for cT3-cT4 urothelial carcinoma in the era of neoadjuvant chemotherapy: a propensity score-matched analysis.
     J Robot Surg. 2025;19:596.
     PubMed    
     Abstract available
     
     

164. ISHII N, Sekine Y, Shinohara M, Kawashima Y, et al
     Effects of Avelumab Maintenance on Advanced Urothelial Carcinoma: A Real-World Multicenter Study.
     Cancer Med. 2025;14:e71241.
     PubMed    
     Abstract available
     
     

165. URUSHIBARA M, Kato D, Okumura T, Kojima A, et al
     Long-Term Survival Obtained by Repeated Cytoreductive Surgery and S-1 Plus Cisplatin Chemotherapy at Each Instance of Disease Progression in a Patient With Metastatic Urachal Carcinoma: A Case Report.
     Cancer Rep (Hoboken). 2025;8:e70317.
     PubMed    
     Abstract available
     
     

166. HAN T, Cui H, Du G, Guan Y, et al
     Expression and Prognostic Significance of Different Antibody-Drug Conjugate Target Proteins in Urachal Carcinoma.
     Clin Genitourin Cancer. 2025;23:102403.
     PubMed    
     Abstract available
     
     

167. YANG T, Sun X, Chen J, Li J, et al
     MS4A4A-positive tumor-associated macrophages associate with poor prognosis and T-cell exhaustion in patients with urothelial carcinoma of the bladder.
     J Pathol. 2025;267:225-239.
     PubMed    
     Abstract available
     
     

168. GALSKY MD, Bajorin DF, Tomita Y, Ye D, et al
     Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial.
     Nat Med. 2025;31:3062-3073.
     PubMed    
     Abstract available
     
     

169. HAN W, Yu X, Chen S, Ou Z, et al
     Clinical Characteristics and Surgical Outcomes of Bladder Paraganglioma: A 20-Year Nationwide Center Experience.
     Clin Genitourin Cancer. 2025;23:102397.
     PubMed    
     Abstract available
     
     

170. KHANI F, Beg S, Park K, Kawaguchi K, et al
     SPINK1 immunohistochemistry: An ancillary tool to diagnose urothelial carcinoma in situ and urothelial dysplasia.
     Pathol Res Pract. 2025;273:156148.
     PubMed    
     Abstract available
     
     

171. SLUSARCZYK A, Scilipoti P, Contieri R, Longoni M, et al
     Comparative Assessment of Chemotherapy Followed by Consolidative Radical Cystectomy Versus Chemoradiation for Clinically Node-Positive Urothelial Carcinoma of the Bladder.
     Clin Genitourin Cancer. 2025;23:102399.
     PubMed    
     Abstract available
     
     

172. LIU L, He LY, Zhang PY, Xiao Y, et al
     Neuroendocrine carcinoma of the bladder: do they have a worse prognosis? A large retrospective cohort study by propensity score matching analysis.
     Int J Surg. 2025;111:6435-6440.
     PubMed    
     Abstract available
     
     

173. LIU L, Li JP, Gao LX, An L, et al
     Risk factors for acute kidney injury following radical cystectomy: a systematic review and meta-analysis.
     Int J Surg. 2025;111:6330-6342.
     PubMed    
     Abstract available
     
     

174. MA B, Ma C, Long X, Jiang L, et al
     Stromal reprogramming in urachal cancer: Fibroblast activation protein and collagen remodeling drive immune-suppressive niches and immunotherapy resistance.
     Int Immunopharmacol. 2025;163:115204.
     PubMed    
     Abstract available
     
     

175. GRIMMEISEN M, Wang X, Weldle M, Sartory K, et al
     Synthesis and Evaluation of Trehalose-Based Mertansine Warheads for Bacillus Calmette-Guerin Delivery of Anticancer Agents.
     Chembiochem. 2025;26:e202500390.
     PubMed    
     Abstract available
     
     

176. OHMOTO A, Kitahama K, Shigematsu Y, Hayashi N, et al
     Genomic features of bladder neuroendocrine carcinoma with composite histology.
     Histol Histopathol. 2025;40:1547-1554.
     PubMed    
     Abstract available
     
     

177. DE ANGELIS M, Jannello LMI, Siech C, Di Bello F, et al
     Race/Ethnicity Affects Access and Survival Differences After Neoadjuvant or Adjuvant Chemotherapy at Radical Cystectomy in Urothelial Carcinoma Patients.
     J Racial Ethn Health Disparities. 2025;12:3284-3293.
     PubMed    
     Abstract available
     
     

178. ZHANG H, Tang K, Chen Y, Chen G, et al
     Downregulated of CTGF reveals mechanism, remodels immune microenvironment, modulates drug sensitivity in bladder cancer.
     Future Sci OA. 2025;11:2560297.
     PubMed    
     Abstract available
     
     

179. JUHASZ D, Csizmarik A, Varadi M, Bacso D, et al
     Lymphovascular Invasion is Predictive for Adjuvant Platinum Therapy Benefit in Urothelial Bladder Cancer.
     Clin Genitourin Cancer. 2025 Sep 1:102421. doi: 10.1016/j.clgc.2025.102421.
     PubMed    
     Abstract available
     
     

180. MATSUBARA N, Loriot Y, Banek S, Valderrama BP, et al
     Fibroblast Growth Factor Receptor Alteration Testing for >3600 Patients with Locally Advanced/Metastatic Urothelial Cancer and Non-muscle-invasive Bladder Cancer: An Analysis of the Global ANNAR Biomarker Study.
     Eur Urol Oncol. 2025 Sep 22:S2588-9311(25)00201.
     PubMed    
     Abstract available
     
     

181. DU Y, Sui Y, Tao Y, Cao J, et al
     Comprehensive Assessment of Tumor Stromal Heterogeneity in Bladder Cancer by Deep Learning and Habitat Radiomics.
     Acad Radiol. 2025 Sep 22:S1076-6332(25)00799-8. doi: 10.1016/j.acra.2025.
     PubMed    
     Abstract available
     
     

182. YONG ZONG AT, Yap WK
     Global Research Trends in Bladder Cancer Biomarkers: A Bibliometric Analysis.
     Cureus. 2025;17:e90724.
     PubMed    
     Abstract available
     
     

183. LIN N, Zhou Y, Li Y, Lin L, et al
     Circulating tumor DNA and Urinary tumor DNA: useful biomarkers for bladder cancer detection.
     Expert Rev Mol Diagn. 2025 Sep 22. doi: 10.1080/14737159.2025.2565273.
     PubMed    
     Abstract available
     
     

184. BOILLAT S, Goasmat V, Derre L, Domingos-Pereira S, et al
     Role of myeloid-derived suppressor cells in bladder cancer and targeted therapeutic strategies.
     Gene. 2025 Sep 20:149772. doi: 10.1016/j.gene.2025.149772.
     PubMed    
     
     
     

185. LIEDBERG F, Hagberg O, Beijert IJ, Aljabery F, et al
     Applicability of the European Association of Urology 2021 Prognostic Model for Non-muscle-invasive Bladder Cancer in a Swedish Population-based Cohort.
     Eur Urol Open Sci. 2025;80:33-37.
     PubMed    
     Abstract available
     
     

186. SUN Y, Yi X, Zhou C, Huang Y, et al
     PAQR4: A Critical Senescence-Related Gene Influencing Immune Evasion and Metastasis in Bladder Urothelial Carcinoma.
     Hum Mutat. 2025;2025:2227219.
     PubMed    
     Abstract available
     
     

187. BUKAVINA L, Isali I, Parekh S, Psutka S, et al
     Genetic susceptibility and environmental risk factors in bladder cancer: Evidence from the UK biobank.
     Bladder Cancer. 2025;11:23523735251370863.
     PubMed    
     Abstract available
     
     

188. RUIZ-LORENTE I, Gimeno L, Lopez-Abad A, Lopez Cubillana P, et al
     Interplay of KIR2DL5, nitric oxide, and tobacco smoking in predisposition to bladder cancer.
     Front Cell Dev Biol. 2025;13:1632101.
     PubMed    
     Abstract available
     
     

189. DEL GIUDICE F, Santarelli V, Laszkiewicz J, Li S, et al
     The influence of immunocompromised status on recurrence and progression free survival among nonmuscle invasive bladder cancers (NMIBCs) undergoing transurethral resection of bladder tumor (TURBT) and adjuvant intravesical bacillus Calmette Guerin (BCG
     Urol Oncol. 2025 Sep 19:S1078-1439(25)00254.
     PubMed    
     Abstract available
     
     

190. ETXANO J, Lopez-Maseda A
     Clinical applications of bladder magnetic resonance imaging: Beyond the VI-RADS(R) classification.
     Radiologia (Engl Ed). 2025;67:101668.
     PubMed    
     Abstract available
     
     

191. MIAO Z, Xu A, Shen G, Tang S, et al
     Fluorinated albumin nanocages dually target CAFs and tumor cells to potentiate bladder cancer chemoimmunotherapy.
     J Control Release. 2025;387:114246.
     PubMed    
     Abstract available
     
     

192. YING W, Li D, Feng N, Wei W, et al
     LncRNA DGUOK-AS1 Promotes Bladder Cancer Progression by Enhancing EFTUD2 Stability.
     Cancer Res Treat. 2025 Sep 18. doi: 10.4143/crt.2025.
     PubMed    
     Abstract available
     
     

193. CHENG Y, Zhou K, Chen Y, Mei Y, et al
     Concurrent Ferroptosis and Pyroptosis Induced by a Dual-Organelle-Targeted Type I/II AIE Photosensitizer for Bladder Cancer Immunotherapy.
     Angew Chem Int Ed Engl. 2025 Sep 18:e202509783. doi: 10.1002/anie.202509783.
     PubMed    
     Abstract available
     
     

194. ALONSO JCC, Goncalves JM, de Arruda Camargo GC, de Oliveira G, et al
     Dual molecular axis of resistance and immunoresponsiveness to BCG in pT1 non-muscle invasive bladder cancer: Insights from HER-2, SERBP1, HABP4, and IFN-gamma profiling.
     Tissue Cell. 2025;98:103137.
     PubMed    
     Abstract available
     
     

195. ZHANG T, Zhang H, Qi J, Jiang S, et al
     Hollow Dodecahedral Nanocages for Reliable Multi-Level Differentiation of Urological Cancers through Non-Invasive Metabolic Fingerprinting.
     Anal Chem. 2025;97:20622-20631.
     PubMed    
     Abstract available
     
     

196. JANG A, Tripathi N, Lanka SM, Kumar HLS, et al
     Advanced urothelial carcinoma treated with enfortumab vedotin and pembrolizumab: a path to cure?
     Oncologist. 2025;30:oyaf259.
     PubMed    
     Abstract available
     
     

197. VAN TASSEL E, Howell J, Walls K, Crabtree W, et al
     Outcome of atypical urothelial cells (AUC) in patients without prior history of urothelial carcinoma.
     J Am Soc Cytopathol. 2025;14:334-340.
     PubMed    
     Abstract available
     
     

198. TATAR AC, Loghin A, Nechifor-Boila A, Raicea A, et al
     IHC-based molecular classification in muscle-invasive urothelial bladder carcinoma: Prognostic and predictive value toward a clinically applicable IHC marker panel - A systematic review.
     Crit Rev Oncol Hematol. 2025;214:104868.
     PubMed    
     Abstract available
     
     

199. GRIVAS P, Moon HH
     A Podcast on Real-World Evidence with Avelumab First-Line Maintenance and Treatment Sequencing in Locally Advanced or Metastatic Urothelial Carcinoma.
     Target Oncol. 2025;20:743-754.
     PubMed    
     Abstract available
     
     

200. POWLES TB, Van der Heijden MS, Loriot Y, Bedke J, et al
     Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302/KEYNOTE-A39 trial.
     Ann Oncol. 2025;36:1212-1219.
     PubMed    
     Abstract available
     
     

201. GRIVAS P, Aragon-Ching JB, Bellmunt J, Loriot Y, et al
     Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Analyses of Patient-reported Outcomes and Quality-adjusted Time Without Symptoms or Toxicity from the JAVELIN Bladder 100 Trial.
     Eur Urol Oncol. 2025;8:941-951.
     PubMed    
     Abstract available
     
     

202. JAIN RK, Swami U, Bilen MA, Gebrael G, et al
     Cabozantinib plus Pembrolizumab as First-line Therapy for Cisplatin-ineligible Advanced Urothelial Carcinoma: The PemCab Trial.
     Eur Urol Oncol. 2025;8:952-960.
     PubMed    
     Abstract available
     
     

203. CAO M, Yang G, Zhao T, Zhang L, et al
     Development and Validation of the UriMee Model: A Methylation-based Diagnostic Tool for Early Diagnosis of Urothelial Carcinoma.
     Eur Urol Oncol. 2025;8:899-908.
     PubMed    
     Abstract available
     
     

204. GUO E, Chen L, Xu L, Zhang D, et al
     Optimizing bladder magnetic resonance imaging: accelerating scan time and improving image quality through deep learning.
     Abdom Radiol (NY). 2025;50:4772-4782.
     PubMed    
     Abstract available
     
     

205. RUTTEN VC, Hesseling SAW, Franckena M, Zuiverloon TCM, et al
     Carbon footprint and staff demands of surgery and chemoradiation for muscle-invasive bladder cancer.
     BJU Int. 2025 Sep 3. doi: 10.1111/bju.16876.
     PubMed    
     Abstract available
     
     

206. FAZILI A, Jazayeri SB, Rose KM, Guske C, et al
     Cisplatin-ineligible patients with muscle-invasive bladder cancer demonstrate poor long-term survival following immediate radical cystectomy.
     BJU Int. 2025 Sep 11. doi: 10.1111/bju.16895.
     PubMed    
     Abstract available
     
     

207. CLEMENTS MB, Pekala KR, Tin AL, Sjoberg DD, et al
     Prospective health-related quality of life in women undergoing radical cystectomy and urinary diversion.
     BJU Int. 2025;136:728-737.
     PubMed    
     Abstract available
     
     

208. KALEN E, Ginstman C, Liedberg F, Hagberg O, et al
     Incidence and risk factors for postoperative vaginal events following radical cystectomy for bladder cancer: a nationwide population-based study.
     BJU Int. 2025 Sep 20. doi: 10.1111/bju.70004.
     PubMed    
     Abstract available
     
     

209. STOCKEM CF, Gil-Jimenez A, Ali H, van Dorp J, et al
     Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study.
     Clin Cancer Res. 2025;31:3897-3906.
     PubMed    
     Abstract available
     
     

210. KITAMURA H, Nishiyama N
     Oncolytic virus therapy for nonmuscle-invasive bladder cancer: current status and future directions.
     Curr Opin Urol. 2025 Sep 8. doi: 10.1097/MOU.0000000000001331.
     PubMed    
     Abstract available
     
     

211. OUALLA K, Alem M, Teoh J
     Systemic immunotherapy for BCG unresponsive nonmuscle-invasive bladder cancer.
     Curr Opin Urol. 2025 Sep 15. doi: 10.1097/MOU.0000000000001334.
     PubMed    
     Abstract available
     
     

212. WONG CH, Leung DK, Gontero P, Teoh JY, et al
     Gene-mediated therapy for BCG-unresponsive nonmuscle-invasive bladder cancer: mechanisms, clinical evidence, and practical implementation.
     Curr Opin Urol. 2025 Sep 19. doi: 10.1097/MOU.0000000000001345.
     PubMed    
     Abstract available
     
     

213. GABRIEL PE, Horowitz A, Sfakianos JP, Xylinas E, et al
     Targeted therapies for Bacillus Calmette-Guerin unresponsive nonmuscle-invasive bladder cancer: a narrative review.
     Curr Opin Urol. 2025 Sep 19. doi: 10.1097/MOU.0000000000001343.
     PubMed    
     Abstract available
     
     

214. DING D, Qian L, Jin D, Zhou X, et al
     Aptamer-based Positron Emission Tomography Imaging Allows Specific Detection of Residual Bladder Cancer: A First-in-Human Study.
     Eur Urol. 2025 Sep 19:S0302-2838(25)00493-2. doi: 10.1016/j.eururo.2025.
     PubMed    
     
     
     

215. ZUGMAN M, Carneiro A, Maluf FC
     Challenging the Guidelines: Rethinking Neoadjuvant Therapy for Histologic Subtypes of Bladder Cancer.
     Eur Urol. 2025 Sep 17:S0302-2838(25)00510-X. doi: 10.1016/j.eururo.2025.
     PubMed    
     
     
     

216. HECK MM, Lehmann J, Amiel T, Rubben H, et al
     Long-term Results from the LEA Randomized Trial: Extended Versus Standard Lymph Node Dissection in Patients with Bladder Cancer Undergoing Radical Cystectomy.
     Eur Urol. 2025 Sep 17:S0302-2838(25)00489-0. doi: 10.1016/j.eururo.2025.
     PubMed    
     Abstract available
     
     

217. PILALA KM, Koroneou S, Papadimitriou MA, Panoutsopoulou K, et al
     Loss of METTL3 m6A methyltransferase results in short-term progression and poor treatment outcome of bladder cancer patients.
     Int J Cancer. 2025 Sep 9. doi: 10.1002/ijc.70147.
     PubMed    
     Abstract available
     
     

218. TILLU N, Dovey Z, Choudhary M, Venkatesh A, et al
     Open Versus Robotic Radical Cystectomy With Intracorporeal Neobladder: A Decade-Long Single-Surgeon Experience.
     Int J Urol. 2025;32:1234-1242.
     PubMed    
     Abstract available
     
     

219. URABE F, Tashiro K, Imai Y, Iwatani K, et al
     Evaluation of Optimal Sequential Treatment Patterns and Clinical Outcomes in Patients With Advanced Urothelial Carcinoma Treated With First-Line Platinum-Based Chemotherapy: A Multicenter Collaborative Study.
     Int J Urol. 2025;32:1147-1156.
     PubMed    
     Abstract available
     
     

220. 
     RETRACTION: Astrocyte Elevated Gene-1 Promotes Invasion and Epithelial-Mesenchymal Transition in Bladder Cancer Cells Through Activation of Signal Transducer and Activator of Transcription 3.
     Int J Urol. 2025 Sep 20. doi: 10.1111/iju.70224.
     PubMed    
     Abstract available
     
     

221. YILDIZ AK, Bayraktar A, Kacan T, Demir DO, et al
     Two different protocols in single, immediate, postoperative intravesical chemotherapy after transurethral resection in suspected, low-risk, non-muscle-invasive bladder cancer.
     Int Urol Nephrol. 2025 Aug 28. doi: 10.1007/s11255-025-04767.
     PubMed    
     Abstract available
     
     

222. NECCHI A, Galsky MD, Dizman N, Aggen DH, et al
     End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer.
     J Clin Oncol. 2025 Sep 11:JCO2501608. doi: 10.1200/JCO-25-01608.
     PubMed    
     Abstract available
     
     

223. DANESHMAND S, Van der Heijden MS, Jacob JM, Guerrero-Ramos F, et al
     Erratum: TAR-200 for Bacillus Calmette-Guerin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study.
     J Clin Oncol. 2025 Sep 9:JCO2502053. doi: 10.1200/JCO-25-02053.
     PubMed    
     
     
     

224. GUTIERREZ J, Ayub A, Piva SE, Shirk JD, et al
     IP11-07 A 3D Tumor Map for the Surgical Management of Bladder Cancer: Feasibility and Preliminary Analysis: Erratum.
     J Urol. 2025;214:458.
     PubMed    
     
     
     

225. WANG Y, Jerome NA, Kelleher AJ, Henderson ML, et al
     TRIM29 promotes bladder cancer invasion by regulating the intermediate filament network and focal adhesion.
     Oncogene. 2025 Sep 4. doi: 10.1038/s41388-025-03557.
     PubMed    
     Abstract available
     
     

226. XIE J, Zhang H, Wang K, Ni J, et al
     Correction: M6A-mediated-upregulation of lncRNA BLACAT3 promotes bladder cancer angiogenesis and hematogenous metastasis through YBX3 nuclear shuttling and enhancing NCF2 transcription.
     Oncogene. 2025 Sep 17. doi: 10.1038/s41388-025-03575.
     PubMed    
     
     
     

227. WESTERMAN ME, Delacroix SE Jr
     Editorial Comment: Muscle-Invasive Bladder Cancer Treatment Selection in an Emerging Treatment Era: A Patient Preference Study.
     Urology. 2025 Sep 4:S0090-4295(25)00838-6. doi: 10.1016/j.urology.2025.
     PubMed    
     
     
     

228. LI C, Liu J, Wang L, Xiong W, et al
     Mechanisms for fibrate lipid-lowering drugs in enhancing bladder cancer immunotherapy by inhibiting CD276 expression.
     BMC Cancer. 2025;25:1404.
     PubMed    
     Abstract available
     
     

229. HSIEH KL, Huang KH, Chang CP, Tsai HW, et al
     CUB domain-containing protein 1 signaling dysregulates gemcitabine metabolism contributing to therapeutic resistance in T24 cells.
     PLoS One. 2025;20:e0331289.
     PubMed    
     Abstract available
     
     

230. KATO T, Okauchi N, Motegi T, Sakurai M, et al
     Lactic acid regulates antitumor immunity in canine invasive urothelial carcinoma.
     PLoS One. 2025;20:e0332825.
     PubMed    
     Abstract available